HK1137149A1 - Pharmaceutical composition for treatment of diabetic complications - Google Patents

Pharmaceutical composition for treatment of diabetic complications

Info

Publication number
HK1137149A1
HK1137149A1 HK10104542.3A HK10104542A HK1137149A1 HK 1137149 A1 HK1137149 A1 HK 1137149A1 HK 10104542 A HK10104542 A HK 10104542A HK 1137149 A1 HK1137149 A1 HK 1137149A1
Authority
HK
Hong Kong
Prior art keywords
treatment
pharmaceutical composition
diabetic complications
diabetic
complications
Prior art date
Application number
HK10104542.3A
Other languages
English (en)
Inventor
Supreet K Deshpande
Sudhir A Kulkarni
Reena R Gollapudy
Original Assignee
Vlife Sciences Technologies Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlife Sciences Technologies Pvt Ltd filed Critical Vlife Sciences Technologies Pvt Ltd
Publication of HK1137149A1 publication Critical patent/HK1137149A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK10104542.3A 2007-01-29 2010-05-10 Pharmaceutical composition for treatment of diabetic complications HK1137149A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1960MU2006 2007-01-29
PCT/IN2008/000044 WO2008093356A1 (fr) 2007-01-29 2008-01-24 Composition pharmaceutique pour le traitement de complications diabétiques

Publications (1)

Publication Number Publication Date
HK1137149A1 true HK1137149A1 (en) 2010-07-23

Family

ID=47263792

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10104542.3A HK1137149A1 (en) 2007-01-29 2010-05-10 Pharmaceutical composition for treatment of diabetic complications
HK15105526.5A HK1204932A1 (en) 2007-01-29 2015-06-10 Pharmaceutical composition for treatment of diabetic complications

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15105526.5A HK1204932A1 (en) 2007-01-29 2015-06-10 Pharmaceutical composition for treatment of diabetic complications

Country Status (11)

Country Link
US (1) US8686051B2 (fr)
EP (2) EP2114386B9 (fr)
JP (1) JP5240586B2 (fr)
CN (2) CN101616662B (fr)
CA (1) CA2680843C (fr)
CY (1) CY1113784T1 (fr)
DK (1) DK2114386T3 (fr)
ES (1) ES2400004T3 (fr)
HK (2) HK1137149A1 (fr)
WO (1) WO2008093356A1 (fr)
ZA (1) ZA200905970B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2480204T3 (da) * 2009-09-22 2014-02-03 Vlife Sciences Technologies Pvt Ltd Topikal formulering til diabetiske fodsår
EP2804612A4 (fr) * 2012-01-19 2015-09-02 Ibt Pharma Inc Utilisations thérapeutiques du tétrachlorodécaoxygène (tcdo)
US20150111833A1 (en) * 2012-04-20 2015-04-23 Howard University Method Of Treating An Ocular Disease And Compositions Effective For Treating An Ocular Disease
CA2907175C (fr) * 2013-03-15 2022-11-08 M. Alphabet 3, L.L.C. Methodes et compositions permettant d'ameliorer le taux d'oxygene dans des tissus
US20160175485A1 (en) * 2013-08-27 2016-06-23 The Regents Of The University Of California Combination therapy to promote wound healing
JOP20200052A1 (ar) * 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
CN104971211A (zh) * 2014-04-02 2015-10-14 王嘉影 一种用于治疗糖尿病神经源性膀胱病的复方中药汤剂
WO2016108130A1 (fr) * 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Compositions pharmaceutiques topiques comprenant du nébivolol pour le traitement de plaies diabétiques
CN105770860B (zh) * 2016-03-16 2021-01-05 哈尔滨医科大学 生长分化因子-11在促进糖尿病伤口愈合中的用途
WO2018195411A1 (fr) * 2017-04-21 2018-10-25 Steven Hoffman Compositions et méthodes pour le traitement de la rétinopathie
EP3731836B1 (fr) * 2017-12-27 2023-09-20 Genepred Biotechnologies Bêta-bloquants pour le traitement et/ou la prévention des cicatrices pathologiques
EP3787749A4 (fr) * 2018-05-03 2022-01-26 Alimera Sciences, Inc. Méthodes de traitement de maladies rétiniennes
WO2020026471A1 (fr) * 2018-07-31 2020-02-06 株式会社親広産業 Promoteur de la consommation de glucose et promoteur de glycolyse
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
US11154518B2 (en) * 2018-12-28 2021-10-26 Chang Gung Memorial Hospital, Linkou Methods and apparatus for treating a wound
TWI813331B (zh) * 2020-07-10 2023-08-21 長庚醫療財團法人林口長庚紀念醫院 β-1腎上腺素受體拮抗劑用於製備減少表皮生長因子受體抑制劑誘導的上皮細胞損傷以及抑制癌細胞的組合物之用途
CN114053419B (zh) * 2021-12-09 2023-02-24 山东第一医科大学附属青岛眼科医院(山东省眼科研究所、青岛眼科医院) 去甲肾上腺素或β-肾上腺素能受体抑制剂在制备治疗糖尿病神经修复的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL300886A (fr) * 1962-11-23
US3655663A (en) * 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
US4593119A (en) * 1980-11-28 1986-06-03 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
JPS58206519A (ja) 1982-05-27 1983-12-01 Kowa Co 外用β−遮断剤
US4897417A (en) 1988-12-15 1990-01-30 E. I. Du Pont De Nemours & Co. Prodrugs of 3,4-hydroxy benzoyloxypropanolamines
DE69212646T2 (de) 1991-03-18 1997-03-13 Sepracor Inc Zubereitung und verfahren enthaltend optisch reines s-metoprolol
DK1137407T3 (da) 1998-12-11 2004-05-10 Bakulesh Mafatlal Khamar Fremgangsmåde til fremstilling af en formulering af topisk beta-blokkere med forbedret effektivitet
ATE352312T1 (de) 2001-12-29 2007-02-15 Novo Nordisk As Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
WO2006108176A2 (fr) 2005-04-08 2006-10-12 The Regents Of The University Of California Agonistes et antagonistes du recepteur beta 2 adrenergique et modulation de cicatrisation

Also Published As

Publication number Publication date
ES2400004T3 (es) 2013-04-04
CY1113784T1 (el) 2016-07-27
JP5240586B2 (ja) 2013-07-17
CN101616662A (zh) 2009-12-30
HK1204932A1 (en) 2015-12-11
EP2114386B1 (fr) 2012-12-26
CN104189906A (zh) 2014-12-10
ZA200905970B (en) 2012-08-29
CA2680843C (fr) 2016-05-31
CA2680843A1 (fr) 2008-08-07
CN101616662B (zh) 2015-07-29
EP2444077A1 (fr) 2012-04-25
JP2011509917A (ja) 2011-03-31
EP2114386A1 (fr) 2009-11-11
EP2114386B9 (fr) 2013-09-18
WO2008093356A1 (fr) 2008-08-07
US20110021526A1 (en) 2011-01-27
DK2114386T3 (da) 2013-03-18
US8686051B2 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
HK1204932A1 (en) Pharmaceutical composition for treatment of diabetic complications
LT2303330T (lt) Farmacinės kompozicijos, skirtos parkinsono ligai gydyti
ZA200902374B (en) Compositions useful for the treatment of diabetes
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
EP3189859B8 (fr) Composition pour le traitement des maladies du cartilage
IL200090A0 (en) Composition for treatment of undifferentiated-type of gastric cancer
IL199907A0 (en) Composition for treatment of pancreatic cancer
PT2322221E (pt) Composição farmacêutica para tratamento e prevenção de cancro
HK1141447A1 (en) Pharmaceutical composition for the treatment of proliferative diseases
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
EP2213303A4 (fr) Composition pharmaceutique pour le traitement de la cataracte
ZA201009072B (en) Pharmaceutical composition for the treatment of premature ejaculation
GB0909297D0 (en) Composition for the treatment of skin conditions
EP2210621A4 (fr) Composition pour le traitement d'une affection articulaire
EP2172207A4 (fr) Composition pharmaceutique destinée au traitement du diabète et son procédé de préparation
GB2469220B (en) Pharmaceutical composition for treating diabetes and preparation method thereof
EP2301543A4 (fr) Composition pharmaceutique pour traiter le diabète
HK1155659A1 (en) Pharmaceutical composition for treatment of fibromyalgia
PL385972A1 (pl) Kompozycja farmaceutyczna do leczenia chorób przyzębia
EP2305300A4 (fr) Composition pharmaceutique destinée au traitement et à la prévention du cancer
ZA201204341B (en) Pharmaceutical composition for treating gutaneous burns
EP2402342A4 (fr) Composition pharmaceutique servant a traiter le diabete de type 2
HK1145399A1 (en) Pharmaceutical composition for treating hemorrhoids
EP2382992A4 (fr) Composition pharmaceutique destinée au traitement de l'obésité ou du diabète
EP2331099A4 (fr) Compositions pharmaceutiques pour le traitement du diabète sucré